BT
BT1.F Bone Therapeutics SA
- Market cap
- EUR 1.31M
- P/E
- -
- P/B
- 7.38x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2023.
Is BT1.F undervalued?
Graham numberThe Graham number of Bone Therapeutics SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bone Therapeutics SA fundamental analysis
No fundamental analysis for Bone Therapeutics SA yet.
Bone Therapeutics SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bone Therapeutics SA
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Sainte…
Full company profileBone Therapeutics SA financial statements
Bone Therapeutics SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 41.0K | 1.00M | 0.00 | 1.00M | 1.00M | 0.00 | 0.00 |
| Operating Income | -12.8M | -12.3M | -11.5M | -11.2M | -15.0M | -12.0M | -2.32M | -7.04M |
| EBITDA | - | -11.6M | -13.1M | -9.15M | -14.5M | -11.8M | -2.71M | -27.3M |
| Net Income | -13.0M | -12.8M | -14.2M | -10.5M | -11.9M | -12.9M | -2.04M | -28.8M |
| EPS | - | -1.86 | -1.71 | -0.98 | -0.72 | -0.61 | -0.06 | -0.18 |
| Balance Sheet | ||||||||
| Total Assets | 38.6M | 25.2M | 25.8M | 22.4M | 24.8M | 19.8M | 29.3M | 9.56M |
| Total Liabilities | 23.3M | 22.8M | 21.3M | 20.3M | 21.5M | 26.5M | 26.2M | 32.3M |
| Shareholders' Equity | 15.3M | 2.38M | 4.49M | 2.05M | 3.33M | -6.77M | 3.53M | -22.9M |
| Cash & Short-term Investments | 20.3M | 8.41M | 8.17M | 8.63M | 14.6M | 9.51M | 1.85M | 117K |
| Cash Flow | ||||||||
| Operating Cash Flow | -11.4M | -11.0M | -12.9M | -10.4M | -16.1M | -12.8M | -1.91M | -3.47M |
| Capital Expenditure | 579K | 406K | 277K | 289K | 78.0K | 193K | 5.00K | 0.00 |
| Free Cash Flow | - | -11.4M | -13.2M | -10.7M | -16.2M | -13.0M | -1.92M | -3.47M |
| Ratios | ||||||||
| ROE | -85.1% | -535.1% | -316.6% | -510.8% | -359.1% | - | -57.9% | - |
| ROA | -33.7% | -50.7% | -55.2% | -46.7% | -48.1% | -65.4% | -7.0% | -301.1% |
| Net Profit Margin | - | -31,102.4% | -1,421.8% | - | -1,194.0% | -1,292.5% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bone Therapeutics SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | EUR 60.0K | 0.01 | - |
| 2016 | EUR 60.0K | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bone Therapeutics SA
- Insiders 7.61%
- Institutions 0.00%
- Public & others 92.39%
- Shares outstanding 653M
- Free float 603M
Bone Therapeutics SA company profile
- Company name
- Bone Therapeutics SA
- Ticker
- BT1.F
- ISIN
- BE0974280126
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- Avenue Léon champagne, 3, Saintes, Belgium, 1480
- Phone
- 32 478 27 68 42
- Website
- biosenic.com
About Bone Therapeutics SA
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.
Bone Therapeutics SA management
1- Mr. Jean-Luc VandebroekInterim CEO & Director · born 1972